The US government intensified its campaign to reduce pharmaceutical costs, mandating 17 major drugmakers to align Medicaid and Medicare drug prices with the lowest overseas rates under a 60-day ultimatum. President Donald Trump’s executive order seeks comprehensive compliance, including direct-to-consumer sales of heavily rebated drugs and repatriation of profits accrued abroad. The pharmaceutical industry expressed concern over the aggression and potential impacts on innovation and global market dynamics. Ongoing tariff considerations and reimbursement challenges add to the sector’s complex regulatory and pricing environment.